Chinese early-stage cancer screening solutions developer Creative Biosciences (Guangzhou) Co., Ltd, on Sunday announced that it has pocketed 600 million yuan ($88 million) in a Series C round led by healthcare-focused private equity firm Tsing Song Capital.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
